Halozyme Therapeutics Inc (NASDAQ: HALO) has reported E.P.S. of $1.08 for its third fiscal quarter (ending September 30) versus $0.62 for the same period a year ago — an increase of 74%. E.P.S. were $3.08 for the latest four quarters through September 30 versus $1.91 for the same period a year ago — an increase of 61%.
Recent Price Action
Halozyme Therapeutics Inc (NASDAQ: HALO) stock declined slightly by -0.04% on 10/31/24. The stock closed at $50.57. Moreover, this decline was accompanied by above average trading volume at 144% of normal. The stock has been exceptionally strong relative to the market over the last nine months but is unchanged during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, HALO is expected to continue to be a major Value Builder.
Halozyme Therapeutics has a current Value Trend Rating of A (Highest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Halozyme Therapeutics has a very high Power Rating of 91 and a very high Appreciation Score of 98, triggering the Highest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment